Safety of bevacizumab in patients with non-small-cell lung cancer and brain metastases

Journal of Clinical Oncology

Volumn 27, Issue 31, 2009, Pages 5255-5261

  Socinski, Mark A ^a   Langer, Corey J ^a   Huang, Jane E ^a   Kolb, Margaret M ^a   Compton, Peter ^a   Wang, Lisa ^a   Akerley, Wallace ^a  

^a UNIVERSITY OF NORTH CAROLINA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; CARBOPLATIN; CISPLATIN; DOCETAXEL; ERLOTINIB; GEMCITABINE; NAVELBINE; PACLITAXEL; PEMETREXED; ANTINEOPLASTIC AGENT; DRUG DERIVATIVE; GLUTAMIC ACID DERIVATIVE; GUANINE; MONOCLONAL ANTIBODY; QUINAZOLINE DERIVATIVE;

ACUTE KIDNEY FAILURE; ADULT; AGED; ARTICLE; BRAIN ATHEROSCLEROSIS; BRAIN EDEMA; BRAIN HEMORRHAGE; BRAIN METASTASIS; CANCER GROWTH; CANCER MORTALITY; CLINICAL TRIAL; DRUG SAFETY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; FEMALE; HUMAN; LUNG CANCER; LUNG HEMORRHAGE; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; TREATMENT DURATION; BRAIN TUMOR; LUNG TUMOR; METASTASIS; MIDDLE AGED; PATHOLOGY;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BRAIN NEOPLASMS; CARBOPLATIN; CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; GLUTAMATES; GUANINE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; QUINAZOLINES;

EID: 70449725036     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2009.22.0616     Document Type: Article

References (24)

1. Mintz A, Perry J, Spithoff K, et al: Management of single brain metastasis: A practice guideline. Curr Oncol 14:131-143, 2007
2. Eichler AF, Loeffler JS: Multidisciplinary management of brain metastases. The Oncologist 12: 884-898, 2007
3. Langer CJ, Mehta MP: Current management of brain metastases, with a focus on systemic options. J Clin Oncol 23:6207-6219, 2005
4. Wen PY, Mclaren Black P, Loeffler JS: Metastatic Brain Cancer. In DeVita VT Jr., Hellman S, Rosenberg SA (eds): Cancer Principles and Practice of Oncology, 6th edition. Philadelphia, PA: Lippincott Williams and Wilkins 2655-2670, 1999
5. Bradley KA, Mehta MP: Management of brain metastases. Semin Oncol 31:693-701, 2004
6. Andrews DW, Scott CB, Sperduto PW, et al: Whole brain radiation therapy with or without stereotactic radiosurgery boost for patients with one to three brain metastases: Phase III results of the RTOG 9508 randomised trial. Lancet 363:1665-1672, 2004
7. Gaspar LE, Chansky K, Albain KS, et al: Time from treatment to subsequent diagnosis of brain metastases in stage III non-small-cell lung cancer: A retrospective review by the Southwest Oncology Group. J Clin Oncol 23:2955-2961, 2005
8. Oh Y, Stewart DJ: Systemic therapy for lung cancer brain metastases: A rationale for clinical trials. Oncology (Williston Park) 22:168-178, 2008
9. Nguyen T, DeAngelis LM: Treatment of Brain Metastases. J Support Oncol 2:405-416, 2004
10. Carden CP, Larkin JM, Rosenthal MA: What is the risk of intracranial bleeding during anti-VEGF therapy? Neuro Oncol 10(4):624-630, 2008
11. Bitoh S, Hasegawa H, Ohtsuki H, et al: Cerebral neoplasms initially presenting with massive intracerebral hemorrhage. Surg Neurol 22:57-62, 1984
12. Mandybur TI: Intracranial hemorrhage caused by metastatic tumors. Neurology 27:650-655, 1977
13. Suzuki H, Toyoda S, Muramatsu M, et al: Spontaneous haemorrhage into metastatic brain tumours after stereotactic radiosurgery using a linear accelerator. J Neurol Neurosurg Psychiatry 74:908-912, 2003
14. Cohen NR, Tan TS, Barker CS: Intracerebral haemorrhage secondary to metastasis from presumed non-small cell lung carcinoma. Neuropathol Appl Neurobiol 30:419-422, 2004
15. Ho KL: Neoplastic aneurysm and intracranial hemorrhage. Cancer 15; 50:2935-2940, 1982
16. Sandler A, Gray R, Perry MC, et al: Paclitaxel-Carboplatin Alone or with Bevacizumab for Non-Small-Cell Lung Cancer. N Engl J Med 355:2542-2550, 2006
17. Avastin® (bevacizumab) [package insert]. South San Francisco, CA: Genentech, Inc, 2007
18. Johnson DH, Fehrenbacher L, Novotny WF, et al: Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol 22:2184-2191, 2004
19. Somer RA, Sherman E, Langer CJ, et al: Restrictive eligibility limits access to newer therapies in non-small-cell lung cancer: The implications of Eastern Cooperative Oncology Group 4599. Clin Lung Cancer 9:102-105, 2008
20. Archer V, Reck M, Sandler AB, et al: Risk of symptomatic central nervous system (CNS) progression and secondary hemorrhage in patients with non-squamous non-small cell lung cancer (NSCLC) receiving bevacizumab (BV)-based first-line therapy. J Clin Oncol 26, 2008 (May 20 suppl; abstr 8114)
21. Shepherd FA, Rodrigues Pereira J, Ciuleanu T, et al: Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 353:123-132, 2005
22. Herbst RS, Johnson DH, Mininberg E, et al: Phase I/II trial evaluating the anti-vascular endothelial growth factor monoclonal antibody bevacizumab in combination with the HER-1/epidermal growth factor receptor tyrosine kinase inhibitor erlotinib for patients with recurrent non-small-cell lung cancer. J Clin Oncol 23:2544-2555, 2005
23. Tarceva® (erlotinib) [package insert]. South San Francisco, CA: Genentech, Inc, 2007
24. Akerley W, Langer C, Oh Y, et al: Acceptable safety of bevacizumab therapy in patients with brain metastases due to non-small cell lung cancer, J Clin Oncol 26, 2008 (May 20 suppl; abstr 8043)